Literature DB >> 35031096

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.

Don Husereau1, Michael Drummond2, Federico Augustovski3, Esther de Bekker-Grob4, Andrew H Briggs5, Chris Carswell6, Lisa Caulley7, Nathorn Chaiyakunapruk8, Dan Greenberg9, Elizabeth Loder10, Josephine Mauskopf11, C Daniel Mullins12, Stavros Petrou13, Raoh-Fang Pwu14, Sophie Staniszewska15.   

Abstract

Health economic evaluations are comparative analyses of alternative courses of action in terms of their costs and consequences. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, published in 2013, was created to ensure health economic evaluations are identifiable, interpretable, and useful for decision making. It was intended as guidance to help authors report accurately which health interventions were being compared and in what context, how the evaluation was undertaken, what the findings were, and other details that may aid readers and reviewers in interpretation and use of the study. The new CHEERS 2022 statement replaces previous CHEERS reporting guidance. It reflects the need for guidance that can be more easily applied to all types of health economic evaluation, new methods and developments in the field, as well as the increased role of stakeholder involvement including patients and the public. It is also broadly applicable to any form of intervention intended to improve the health of individuals or the population, whether simple or complex, and without regard to context (such as health care, public health, education, social care, etc). This summary article presents the new CHEERS 2022 28-item checklist and recommendations for each item. The CHEERS 2022 statement is primarily intended for researchers reporting economic evaluations for peer reviewed journals as well as the peer reviewers and editors assessing them for publication. However, we anticipate familiarity with reporting requirements will be useful for analysts when planning studies. It may also be useful for health technology assessment bodies seeking guidance on reporting, as there is an increasing emphasis on transparency in decision making.
Copyright © 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35031096     DOI: 10.1016/j.jval.2021.11.1351

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  13 in total

1.  Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China.

Authors:  Haijing Guan; Chunping Wang; Zhigang Zhao; Sheng Han
Journal:  Adv Ther       Date:  2022-05-29       Impact factor: 4.070

2.  A critical assessment framework to identify, quantify and interpret the sources of uncertainty in cost-effectiveness analyses.

Authors:  Gergő Merész; Veronika Dóczy; Áron Hölgyesi; Gergely Németh
Journal:  BMC Health Serv Res       Date:  2022-06-25       Impact factor: 2.908

3.  Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain.

Authors:  Federico Argüelles-Arias; Fernando Bermejo; Joaquín Borrás-Blasco; Eugeni Domènech; Beatriz Sicilia; José M Huguet; Antonio Ramirez de Arellano; William J Valentine; Barnaby Hunt
Journal:  Therap Adv Gastroenterol       Date:  2022-05-09       Impact factor: 4.802

4.  Nothing to Cheer About: Endorsing  Imaginary Economic Evaluations and Value Claims with CHEERS 22.

Authors:  Paul Langley
Journal:  F1000Res       Date:  2022-02-28

5.  Frozen section telepathology service: Efficiency and benefits of an e-health policy in South Tyrol.

Authors:  Ilaria Girolami; Stefania Neri; Albino Eccher; Matteo Brunelli; Mattew Hanna; Liron Pantanowitz; Esther Hanspeter; Guido Mazzoleni
Journal:  Digit Health       Date:  2022-07-29

6.  Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.

Authors:  Taihang Shao; Yinan Ren; Mingye Zhao; Wenxi Tang
Journal:  Front Public Health       Date:  2022-08-15

7.  Cost-Utility Analysis of Sacroiliac Joint Fusion in High-Risk Patients Undergoing Multi-Level Lumbar Fusion to the Sacrum.

Authors:  Stacey J Ackerman; Gurvinder S Deol; David W Polly
Journal:  Clinicoecon Outcomes Res       Date:  2022-08-08

8.  First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis.

Authors:  Xueqiong Cao; Hongfu Cai; Na Li; Bin Zheng; Zhiwei Zheng; Maobai Liu
Journal:  Ther Adv Med Oncol       Date:  2022-09-16       Impact factor: 5.485

9.  Effects of an e-health intervention 'iSupport' for reducing distress of dementia carers: protocol for a randomised controlled trial and feasibility study.

Authors:  Gill Windle; Greg Flynn; Zoe Hoare; Patricia Masterson-Algar; Kieren Egan; Rhiannon Tudor Edwards; Carys Jones; Aimee Spector; Katherine Algar-Skaife; Gwenllian Hughes; Paul Brocklehurst; Nia Goulden; Debbie Skelhorn; Joshua Stott
Journal:  BMJ Open       Date:  2022-09-21       Impact factor: 3.006

10.  An Integrated Cost Model Based on Real Patient Flow: Exploring Surgical Hospitalization.

Authors:  Bruno Barbosa Vieira; Augusto da Cunha Reis; Alan de Paiva Loures; Eliel Carlos Rosa Plácido; Fernanda Ferreira de Sousa
Journal:  Healthcare (Basel)       Date:  2022-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.